JB Chemicals & Pharmaceuticals Limited — Investor Meet, 12-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: JB Chemicals & Pharmaceuticals reported revenues of ₹1,001 crore for Q2 FY25, reflecting a year-on-year increase of 13%. Gross margins held steady at 66.2%, while operating EBITDA reached ₹285 crore, marking a 13% growth. Net profit surged 16% to ₹175 crore. Domestic sales rose significantly, comprising 59% of total revenues, with a 22% growth to ₹588 crore. Notably, the company outperformed the IPM with 11% growth against a 7.6% industry average.

2. **Future Outlook and Growth Drivers**: Management is optimistic about continued domestic market outperformance, driven by brand strength and market share gains, particularly in chronic disease categories. The international segment is expected to recover in H2 FY25, buoyed by strong order books and new product launches.

3. **Order Book and Operational Updates**: The international business slightly grew by 3% to ₹413 crore, while the CDMO segment faced short-term challenges with growth projected to rebound in Q3 FY25. The company has a solid pipeline for new launches and expansion in emerging markets, eyeing a $100 million target in the CDMO space within 3-5 years.

4. **Analyst Q&A Insights (Detailed)**:

- **Revenue and Profitability**: Analysts probed revenue projections, with management clarifying that the company anticipates continued domestic growth outpacing the market.

- **Market Position and Competitive Landscape**: Questions about competitive threats were addressed by affirming JB Pharma's rise in market rank, especially in cardiology, where they now place 8th.

- **Operational Challenges or Risks**: Queries on supply chain issues were met with confidence regarding resolution in Q3, ensuring a rebound in CDMO business.

- **Capex and Capital Allocation**: Analyst inquiries confirmed a capital expenditure plan of approximately ₹100 crore for FY25, primarily for growth initiatives and machinery.

- **Strategic Priorities and Long-Term Vision**: Discussions highlighted strong brand management, lifecycle management strategies, and plans for innovation in existing product lines.

5. **Market or Regulatory Updates**: Management noted that although global markets are uncertain, consistent domestic performance positions JB Pharma favorably against peers.

6. **Strategic Focus Areas**: Key themes included robust brand management, expansion in chronic care segments, and proactive cost optimization strategies.

7. **Investor Insight**: The financial health and growth prospects suggest a favorable outlook, consistent with a 'buy' position. The company's growth trajectory, reinforced by strong domestic performance and recovery in international operations, presents a compelling investment opportunity despite short-term challenges.